Suchergebnisse - "d'Arminio Monforte, Antonella"

PubPharm (27)

1

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen : The "STORE" Study

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2020

von Gori, A. | Antinori, A. | Vergori, A. | +22

2

Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen : Results from an Observational Cohort Study

enthalten in: Clinical drug investigation | 2019

von Merlini, E. | Cazzaniga, F. | Casabianca, A. | +6

3

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

enthalten in: The Journal of antimicrobial chemotherapy | 2019

von Taramasso, L. | Lorenzini, P. | Di Biagio, A. | +110

4

Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus : the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

enthalten in: The Journal of infectious diseases | 2019

von Ryom, L. | Dilling Lundgren, J. | Reiss, P. | +14

5

Cardiovascular disease and use of contemporary protease inhibitors : the D:A:D international prospective multicohort study

enthalten in: The lancet. HIV | 2018

von Ryom, L. | Lundgren, J. | El-Sadr, W. | +13

CommentIn: Lancet HIV. 2018 Jun;5(6):e267-e269. - PMID 29731408

6

Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir : data from the ICONA Cohort

enthalten in: HIV clinical trials | 2018

von d'Arminio Monforte, A. | Lorenzini, P. | Cozzi-Lepri, A. | +10

7

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients

enthalten in: PloS one | 2017

von Gianotti, N. | Cozzi-Lepri, A. | Antinori, A. | +11

8

Atazanavir/ritonavir monotherapy : 96 week efficacy, safety and bone mineral density from the MODAt randomized trial

enthalten in: The Journal of antimicrobial chemotherapy | 2016

von Galli, L. | Spagnuolo, V. | Bigoloni, A. | +55

9

T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters : results from a retrospective, ex vivo study

enthalten in: Antiviral therapy | 2016

von Tincati, C. | Savoldi, A. | Cannizzo, E. | +6

10

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice

enthalten in: PloS one | 2016

von Costarelli, S. | Cozzi-Lepri, A. | Lapadula, G. | +10